PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review

Agenus’ recent submission of balstilimab joins novel checkpoint inhibitors from Incyte expecting FDA action this year; Junshi and Coherus’ ongoing rolling BLA for toripalimab is the first from the multiple PD-1/L1 inhibitor candidates developed in China that are vying to enter the US market.

Pipeline
The sun is still shining on the PD-1 pipeline.

The cancer immunotherapy space has no lack of PD-1/L1 immune checkpoint inhibitors, from the Opdivo (nivolumab) and Keytruda (pembrolizumab) juggernauts to more niche players like Sanofi US and Regeneron Pharmaceuticals, Inc.’s Libtayo (cemiplimab), but the lineup nonetheless is poised to expand even more in 2021. One just got approved by the US FDA, three novel PD-1/L1 inhibitors are under review, and more are advancing through pivotal trials.

FDA is in middle of a fire and ice month for the category, having just cleared GlaxoSmithKline plc’s Jemperli...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>